Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kynapid vernakalant IV regulatory update

An FDA advisory committee voted 6-2 to recommend approval of Kynapid vernakalant IV to treat acute

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE